Humacyte, Inc. 10-Q

Item 3. Quantitative and Qualitative Disclosures About Market Risk We are exposed to market risk in the ordinary course of business. As of September 30, 2021 and December 31, 2020, we were not subject to any material market, currency, or interest rate risk. Our primary exposure to market risk is associated with changes in interest rates related to the interest income from our cash and cash equivalents of $240.4 million and $39.9 million as of September 30, 2021 and December 31, 2020, respectively, which we invest in money market funds invested only in obligations of the U.S. government and its agencies. Due to the short-term maturities and low risk profile of our cash and cash equivalents, an immediate 10.0% change in interest rates would not have a material effect on our financial position or results of operations.